Hepatitis C virus replication and potential targets for direct-acting agents.

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Hepatitis C virus (HCV) infection treatment has historically relied on interferon-based therapies.
• Significant advancements in understanding the HCV life cycle have identified new therapeutic targets.

Purpose of the Study:

• To review the development of novel, oral, direct-acting antiviral agents for HCV infection.
• To discuss the potential of protease inhibitors and future multidrug regimens in HCV therapy.

Main Methods:

• Review of preclinical and clinical trial data for direct-acting antivirals.
• Analysis of the viral life cycle to identify therapeutic targets.
• Evaluation of current and future HCV treatment strategies.

Main Results:

• Several direct-acting antiviral agents have advanced to Phase 2 and Phase 3 clinical trials.
• Protease inhibitors have shown promising results in Phase 3 trials for HCV treatment.
• Early antiviral compounds faced challenges with in vivo activity and side effects.

Conclusions:

• Protease inhibitors are expected to be among the first oral direct-acting antivirals available for HCV.
• The future of HCV treatment involves multidrug oral regimens targeting various viral components.
• The ultimate goal is to develop interferon-free oral therapies to replace current standards of care.